Cosciens Biopharma Files 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: Aug 14, 2025 · CIK: 1113423
| Field | Detail |
|---|---|
| Company | Cosciens Biopharma INC. (CSCIF) |
| Form Type | 6-K |
| Filed Date | Aug 14, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, administrative
TL;DR
Cosciens Biopharma (fka Aeterna Zentaris) filed a 6-K on 8/14/25, confirming its foreign private issuer status.
AI Summary
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on August 14, 2025. This report is for the month of August 2025 and indicates the company is a foreign private issuer filing under the 1934 Act. The company's principal executive office is located in Toronto, Ontario, Canada.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding the company's status as a foreign private issuer. It confirms their reporting obligations and location.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
- August 14, 2025 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of August 2025.
What is the current name of the company filing this report?
The current name of the company is COSCIENS Biopharma Inc.
What were the former names of COSCIENS Biopharma Inc.?
The company was formerly known as Aeterna Zentaris Inc. and AETERNA LABORATORIES INC.
Where is the principal executive office of COSCIENS Biopharma Inc. located?
The principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Does COSCIENS Biopharma Inc. file annual reports under Form 20-F or Form 40-F?
The registrant indicates it files annual reports under Form 20-F.
Filing Stats: 992 words · 4 min read · ~3 pages · Grade level 15.6 · Accepted 2025-08-14 17:20:01
Filing Documents
- form6-k.htm (6-K) — 31KB
- ex99-1.htm (EX-99.1) — 55KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001493152-25-012012.txt ( ) — 100KB
forward-looking statements
forward-looking statements. Forward-looking synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company. Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following: the Company’s patented technologies and value-driving products, and development thereof; the extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related products; the successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan from yeast, as well as such products’ capability to address unmet needs within the nutraceuticals markets; Macrilen® (macimorelin) and the Company’s plans in respect of same, including commercialization. the Company’s business strategy; the strategic decision to sunset the Company’s Amyotrophic Lateral Sclerosis (ALS), AIM Biologicals and Delayed Clearance Parathyroid Hormone (DC-PTH) programs ; the transition to a new presidential administration in the United States, including the potential use and effects of tariffs to address the administration’s policy goals, could materially impact our costs and revenues, as well as the macroeconomic framework in which we operate. the Company’s positioning in its target markets; the Company’s ability to accelerate the scale-up of PGX Technology towards commercial levels; expectations for completion of the Company’s Edmonton facility and Natex Termitz facility; pre-clinical and clinical studies and trials and their expected timing and results, including the potential to bring certain products to market following such studies and trials; the ab